Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Products > Oncology > Flashcards

Oncology Flashcards

1
Q

Libtayo: generic name?

A

Cemiplimab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cemiplimab: brand name?

A

Libtayo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Libtayo: indication?

A

Advanced cutaneous squamous-cell carcinoma (CSCC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Libtayo: mechanism of action?

A

PD-1 inhibitor: blocks PD-1 receptor on T-cells, thus preventing cancer cells from connecting and inactivating the T-cell.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Libtayo: administration?

A

350 mg IV, 30 mins every 3 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Libtayo: partner?

A

Regeneron / Sanofi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Libtayo: main competition?

A

Pembrolizumab (Keytruda)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tarlatamab: brand name?

A

Imdelltra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Imdeltra: generic name?

A

Tarlatamab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tarlatamab: indication?

A

Investigational:
Small-cell lung cancer (SCLC), after failure of previous treatment(s)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tarlatamab: mechanism of action?

A

Bispecific T-cell engager (BiTE), attaches to both T-cell (CD3) and cancer cell (DLL-3), brings them together and enhances cancer cell lysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tarlatamab: administration?

A

IV 10 mg every 2 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tarlatamab: partner?

A

Amgen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Tarlatamab: adverse effect?

A

Cytokine-release syndrome (50% of patients, mostly after 1st dose)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cabometyx: generic name?

A

Cabozantinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cabozantinib: brand name?

A

Cabometyx

17
Q

Cabometyx: partner?

A

Ipsen

18
Q

Cabometyx: Indication(s)?

A
  1. Renal Cell Carcinoma (RCC)
  2. Differentiated Thyroid Cancer (DTC)
  3. Hepatic Cell Carcinoma (HCC)
19
Q

Cabometyx: administration?

A

PO

20
Q

Cabometyx: mechanism of action?

A

MET, AXL and VEGFR blocker (three receptors overexpressed on tumor cells, important for angiogenesis and metastatic spread)

21
Q

Tibsovo: generic name?

A

Ivosidenib

22
Q

Ivosidenib: brand name?

A

Tibsovo

23
Q

Tibsovo: partner?

A

Servier

24
Q

Tibsovo: administration?

A

PO

25
Q

Tibsovo: indication(s)?

A
  1. AML (with susceptible IDH1 mutation)
  2. Cholangiocarcinoma (with susceptible IDH1 mutation) - locally advanced or metastatic
26
Q

Tibsovo: mechanism of action?

A

IDH-1 inhibitor.
Targets mutant IDH1 enzyme, to decrease 2HG levels and restore normal cell differentiation.

27
Q

Vectibix: generic name?

A

Panitumumab

28
Q

Panitumumab: brand name?

A

Vectibix

29
Q

Vectibix: indication(s)?

A

Metastatic colorectal cancer with wild-type RAS gene

30
Q

Vectibix: partner?

A

Amgen

31
Q

Vectibix: mechanism of action?

A

Monoclonal Ab against EGFR

Products (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions